Australia

Telstra Broadcast Services and BT Announce Strategic Alliance to Enhance Global Network Connectivity 

Initial five-year agreement delivers expanded media and broadcast network footprint acrossAsia-Pacific and key regions worldwide, with enhanced access to global markets    SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Telstra Broadcast Services (TBS) and BT have entered into an initial five-year strateg...

2023-11-21 13:30 1424

First Subject Enrolled in Phase 1 Study of MRX-5

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial inAustralia. MRX-5 is a new type of benzodiazepine...

2023-11-20 18:34 1454

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment ofDamian Clarke-Bruce as Managing Director and CEO, effective13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Cha...

2023-11-14 08:27 1346

6clicks GRC Platform Adds Automated Cybersecurity Incident Tracking and Reporting to Meet New SEC Disclosure Requirements

Platform Now Helps Organizations Compile Details of Qualifying Events Centrally for Tracking, Reporting, and Complete Auditability to Ensure Full Compliance and Ease of Management MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- 6clicks , pioneers of the leading AI-p...

2023-11-14 06:29 1441

PYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE

* PYC has developed a new drug candidate for the >5 million people worldwide [1] with Polycystic Kidney Disease (PKD) * This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] * PKD is a life-changing diseas...

2023-11-13 21:00 1437

Beyond2020 Improves Access to Clean Water for 10,000 Rural Malaysians

* Sustainable water fountains in 25 rural Malaysian communities provide clean, safe water, reducing waterborne illnesses ABU DHABI, UAE, Nov. 9, 2023 /PRNewswire/ -- Beyond2020, the UAE-driven humanitarian initiative, has installed water filters in 25 communities in theSabah and Sarawak regions...

2023-11-10 03:27 2396

Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial

SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have no...

2023-11-07 21:58 1375

David Beckham Signs Deal with TEMPUR to Promote The Benefits Of Sleep

LONDON, Nov. 6, 2023 /PRNewswire/ -- TEMPUR, a leading designer, manufacturer, distributor, and retailer of premium bedding products worldwide, has today announced the signing ofDavid Beckham as its newest brand ambassador. 

2023-11-06 11:00 3686

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

* Melbourne ophthalmology company PolyActiva is developing a unique biodegradable ocular implant that provides 6 months of sustained drug delivery for patients with glaucoma, the second most common cause of irreversible blindness. * The interim Phase 2a results demonstrate a sustained >20% re...

2023-11-03 05:15 573

CHIMERIC THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CHM 2101, A NOVEL CDH17 CAR T CELL THERAPY FOR ADVANCED GASTROINTESTINAL CANCERS

* FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy * Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic * Phase 1A clinical trial to initiate patient enrolment in 2024 * Phase 1A clinical trial will enroll patients with advanced Colorecta...

2023-10-31 19:00 1424

Clarity and PSI kick off SAR-bisPSMA Phase III

SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG ("PSI"), a global contract rese...

2023-10-26 21:00 1454

Enfinity Global to partner with Kyushu Electric Power in its operational portfolio in the United States

MIAMI, Oct. 26, 2023 /PRNewswire/ -- Enfinity Global Inc., a leader in renewable energy, today announced a definitive agreement for a minority sale in its 400 MW U.S. operating portfolio to the Japanese utility Kyushu Electric Power Co. Inc. (Kyushu Electric). Upon completion of the deal, Kyushu ...

2023-10-26 14:30 1679

Enfinity Global & ICG complete €400 million equity agreement

MIAMI, Oct. 25, 2023 /PRNewswire/ -- Enfinity Global, a leader in renewable energy, today announced the successful completion of €300 million equity funding from ICG, the global alternative asset manager. Another €100 million of equity funding is expected to close within a one-year period as part...

2023-10-25 21:32 2124

Xailient and Morse Micro Join Forces to Transform the Future of Smart Cameras

Wi-Fi HaLow™ Technology Enables Long-Range, Low-Power Connectivity for Smart Cameras SYDNEY and IRVINE, Calif., Oct. 25, 2023 /PRNewswire/ -- Xailient, the leader in edge artificial intelligence (AI) for computer vision, today announced a strategic partnership with Morse Micro, a fast-growing fa...

2023-10-25 21:05 1754

Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis

MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ...

2023-10-23 21:30 1404

Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, Oct. 13, 2023 /PRNewswire/ -- Acti...

2023-10-13 20:00 2385

AACR OVARIAN CANCER CONFERENCE PRESENTATION

HIGHLIGHTS * Data from preclinical studies in ovarian cancer presented at premier international conference inBoston, USA.  * Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade ser...

2023-10-09 15:18 1369

First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial

SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first ...

2023-10-03 20:58 1973

FlexRule's Decision-Centric Approach® methodology empowers organizations to make quality decisions, fast

MELBOURNE, Australia, Sept. 28, 2023 /PRNewswire/ -- FlexRule®, a leading Decision Management Suite, is proud to announce that its Decision-Centric Approach® has been officially trademarked. The Decision-Centric Approach® is a methodology that brings people, rules, data, and processes together...

2023-09-28 12:32 1524

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update

Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints. UK sites added to the XanaCIDD trial of cognitive impairment associated with depression, due to report resu...

2023-09-26 20:51 1510
1 ... 45678910 ... 55